Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation



    Author review: M R Stratton β€” concise summary

    Provided author metrics (h-index 5; total citations 238; 7 papers) indicate a small-to-moderate academic footprint concentrated in clinical/pathology topics (e.g., thyroid, bladder, colorectal genetics, HIV/brain infection, carcinoid/prostate). Strengths: topic diversity across endocrinology, oncology, infection; several clinically-oriented studies. Weaknesses: low publication count, modest citation impact, limited available metadata (no listed affiliations), and unclear recent activity β€” all limit influence and reproducibility assessments.

    Key next step: run an automated bibliometric + content scan to disambiguate this author across databases and evaluate individual paper quality (methodology, sample size, venue) β€” click to run a deeper BGPT agent.




     Long Explanation



    Author Review β€” M R Stratton

    Visual summary (publications & citations)

    What the supplied metrics show

    • Scale of output: 7 listed papers β€” small publication record consistent with a limited academic footprint.
    • Citation impact: total citations 238 with h-index β‰ˆ5 β€” indicates some papers attracted attention but no high-impact, highly-cited flagship paper.
    • Topical breadth: papers cover endocrine pathology (thyroid, prostate), oncology (carcinoid, colorectal predisposition), infection (HIV brain infection), and immunology (interferon & glia) β€” suggests clinical/pathology focus rather than a single concentrated research program.
    • Metadata gaps: no affiliations supplied in the dataset, and OpenAlex-like matches show ambiguity across similarly named authors β€” disambiguation needed before strong claims about institutional standing or career stage.

    Paper-level quick scan (titles provided)

    Listed papers (titles only) indicate a mix of clinical case reports/observational pathology studies and some genetics/infection work. These kinds of papers often vary widely in evidence strength β€” below we score likely quality signals.

    Evidence-quality notes and likely limitations

    • Many titles indicate case reports or small observational pathology series (e.g., endocrine differentiation in inflamed bladder epithelium; co-secretion by a carcinoid metastasis), which are hypothesis-generating but low in hierarchical evidence (no randomized trials, likely small n, limited external validity).
    • A genetics paper claiming a new predisposition locus on 15q14-q22 requires replication and modern linkage/sequence-level data; without methods/replication details its claim strength is uncertain.
    • Older virology/glia/interferon studies (e.g., interferon effects on glial cells) can be valuable but may be superseded by later molecular insights; date and methods matter for current relevance.
    • Absence of clear affiliations and limited publication count hamper reproducibility checks, conflict-of-interest assessment, and evaluation of laboratory resources.

    Concrete strengths

    • Interdisciplinary span (endocrine pathology, oncology genetics, virology/neuropathology) β€” useful for clinical observations linking systemic and local disease processes.
    • Some papers appear to address mechanistic questions (e.g., HIF-1 alpha as a thyroid-responsive protein; interferon effects), which, if well-executed, raise the work above purely descriptive case reports.

    What is missing / blindspots

    • No clear information on study sample sizes, statistical methods, or whether results were reproduced β€” major limits on assessing robustness.
    • Unknown peer-review venues and impact factors for the listed papers β€” we cannot confidently assess editorial standards.
    • No funding / conflict-of-interest declarations provided β€” potential source of unassessed biases.

    External data note (related methodological paper supplied)

    A separate methodological source provided in the dataset (High Cell-Density Fermentation) describes rigorous experimental control in Pichia pastoris fermentations; this is cited below to illustrate the type of method-level evidence that strengthens a paper when present (detailed protocols, measurements, reproducibility statements).

    Key excerpt (methodological relevance):

    Actionable recommendations (next steps to evaluate M R Stratton rigorously)

    1. Disambiguate author identity across bibliographic databases (PubMed, Scopus, OpenAlex, ORCID) and map DOIs/venues for each listed paper.
    2. For each paper: extract year, journal, sample sizes, methods, statistical tests, funding and COI statements, and replication/validation experiments.
    3. Compute per-paper citation trajectories (citations/year), and identify whether citations are methodologically supportive or critical (citation context analysis).
    4. If genetics linkage claims exist (15q14-q22), check for later replication or refutation in subsequent literature and modern sequencing data.

    Interpretive conclusion (evidence-weighted)

    Based on the supplied metrics and paper titles, M R Stratton appears to be a clinician-scientist or pathologist with a small but interdisciplinary output consisting largely of descriptive and mechanistic studies of clinical material. Scientific influence is modest (h-index ~5, 238 citations overall), and current data gaps (affiliation, methods, sample sizes, and venues) substantially limit confidence in claims of high rigor or field-shaping impact. A targeted bibliometric and methods extraction pipeline would resolve the main unknowns β€” we offer to run it now.

    Note: this review uses the author metrics and paper list provided in the prompt; it does not assume additional external material about this specific author beyond the dataset you supplied.


    Feedback:   

    Updated: March 15, 2026

    BGPT Author Review



    Scientific Quality

    30%

    Small publication count (7) and modest citation totals (238) with h-index β‰ˆ5 indicate limited influence and a mostly descriptive/clinical publication profile; lack of affiliation data, unknown venues, and missing methodological metadata reduce confidence in experimental rigor and reproducibilityβ€”strengths are topical breadth and some mechanistic work.



    Communication Quality

    50%

    Paper titles are clear and intelligible and suggest clinically relevant observations; however, absence of abstracts/methods in the provided data prevents judging clarity of methods, data presentation, and statistical transparency.



    Author Novelty

    40%

    Some papers (e.g., proposed new predisposition locus, novel hormone–wound-healing links) hint at novel claims, but novelty is unproven without replication, method detail, or high-impact citation patterns.



    Scientific Rigor

    30%

    Insufficient metadata: unknown sample sizes, journals, methods, and peer-review context; titles imply several case-based/observational reports which are lower on the evidence hierarchy; without methods and replication, rigor cannot be confidently established.

     Analysis Wizard



    Automating author disambiguation and per-paper metadata extraction (DOI, journal, year, citations) from Crossref/OpenAlex to produce reproducible bibliometrics for each listed paper.



     Hypothesis Graveyard



    Strong claim: the 15q14–q22 locus fully explains inherited colorectal adenoma risk β€” falsified unless replicated in independent cohorts and sequence-level causal variants identified.


    Strong claim: interferon effects on glial cells directly predict in vivo neurotoxicity across HIV isolates β€” unlikely without robust in vivo or human neuropathology correlation.

     Science Art


    Author Review: M R Stratton Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT